Oligonucleotide therapeutics have started to live up to early potential after nearly 50 years of research and development, billions in investment, and countless hours of scientific due diligence. Some experts surveyed predict Oligonucleotide and Peptide therapeutics could represent up to 15% of marketed biologic products within five years.
Today, the markets for Oligonucleotides have shifted due to the numerous approvals, Oligonucleotide drugs in development, and applications for use in gene therapies. Manufacturing challenges have emerged including high cost, hazardous waste/byproducts, and energy intensive processes associated with manufacturing these types of products.
Fortunately, new initiatives such as liquid phase synthesis and enzymatic siRNA synthesis technologies can provide highly scalable, cost effective, and sustainable approaches to addressing the sustainability challenges associated with Oligo manufacturing.
In this webinar, industry expert, Yuki Shinohara, AJIPHASE®︎ team member at Aji Bio-Pharma Services shared about sustainable Oligo manufacturing approaches that can save time, cost, and resources – while improving purity, quality, and scalability of these promising therapeutics.
Key Learning Objectives:
- The approach to “sustainable” oligonucleotide manufacturing with unique technologies –AJIPHASE® and enzymatic method
- How liquid-phase oligonucleotide synthesis technology reduces the usage of raw materials
- How the Enzymatic method is able to simplify the purification process in manufacturing